

David Hedley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7814376/david-hedley-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

4,786
citations

35
h-index

69
g-index

82
ext. papers

5,598
ext. citations

5
avg, IF

4.89
L-index

#	Paper	IF	Citations
76	An Iodinated DAPI-Based Reagent for Mass Cytometry. <i>ChemBioChem</i> , 2021 , 22, 532-538	3.8	2
75	Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, In or β particle emitting, Lu. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020 , 5, 22	5.8	5
74	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019 , 49, 1457-1973	6.1	485
73	Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 1195-1200	3.5	3
72	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. <i>Cancer Cell</i> , 2019 , 35, 267-282.e7	24.3	80
71	Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2019 , 50, 801-807	1.6	5
70	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019 , 15, e1006596	5	29
69	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 1344-1354	12.9	240
68	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 73-79	3.8	16
67	The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. <i>Oncotarget</i> , 2018 , 9, 20439-20450	3.3	9
66	EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG Chains for MicroPET/CT Imaging of Patient-Derived Pancreatic Cancer Xenografts. <i>ACS Biomaterials Science and Engineering</i> , 2017 , 3, 279-290	5.5	7
65	Staining of Frozen and Formalin-Fixed, Paraffin-Embedded Tissues with Metal-Labeled Antibodies for Imaging Mass Cytometry Analysis. <i>Current Protocols in Cytometry</i> , 2017 , 82, 12.47.1-12.47.8	3.6	19
64	Guidelines for the use of flow cytometry and cell sorting in immunological studies. <i>European Journal of Immunology</i> , 2017 , 47, 1584-1797	6.1	359
63	Long term responders to palliative chemotherapy for advanced biliary tract cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 352-360	2.8	8
62	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2017 , 3, 774-783	13.4	157
61	Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. <i>British Journal of Cancer</i> , 2017 , 116, 50-57	8.7	14
60	Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts. <i>Oncotarget</i> , 2017 , 8, 1392-1404	3.3	7

59	Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. <i>Angewandte Chemie</i> , 2016 , 128, 13353-13357	3.6	7
58	Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. <i>Angewandte Chemie - International Edition</i> , 2016 , 55, 13159-13163	16.4	25
57	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 994-1002	4	1
56	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI?9041). <i>Investigational New Drugs</i> , 2016 , 34, 104-11	4.3	13
55	Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. <i>Journal of Clinical Pathology</i> , 2016 , 69, 695-701	3.9	8
54	Cytokinetic effects of Wee1 disruption in pancreatic cancer. <i>Cell Cycle</i> , 2016 , 15, 593-604	4.7	8
53	A phase I study of elesclomol sodium in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2437-40	1.9	23
52	The clinical significance of hypoxia in human cancers. <i>Seminars in Nuclear Medicine</i> , 2015 , 45, 110-21	5.4	133
51	Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3124-9	2.2	241
50	Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. <i>Journal of Controlled Release</i> , 2015 , 206, 122-30	11.7	83
49	Outcome of adjuvant therapy in biliary tract cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 382-7	2.7	28
48	Whole blood measurement of histone modifications linked to the epigenetic regulation of gene expression. <i>Current Protocols in Cytometry</i> , 2015 , 71, 6.36.1-6.36.9	3.6	
47	The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014 , 85, 78-87	4.6	10
46	Identification of hypoxic cells using an organotellurium tag compatible with mass cytometry. <i>Angewandte Chemie - International Edition</i> , 2014 , 53, 11473-7	16.4	34
45	Identification of Hypoxic Cells Using an Organotellurium Tag Compatible with Mass Cytometry. <i>Angewandte Chemie</i> , 2014 , 126, 11657-11661	3.6	3
44	Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts. <i>Cancers</i> , 2014 , 6, 459-71	6.6	49
43	Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. <i>European Journal of Cancer</i> , 2013 , 49, 329-35	7.5	88
42	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2012 , 30, 779-86	4.3	40

41	Emerging applications of flow cytometry in solid tumor biology. <i>Methods</i> , 2012 , 57, 359-67	4.6	21
40	Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. <i>Cancer</i> , 2012 , 118, 3105-15	6.4	47
39	A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2012 , 30, 1203-7	4.3	16
38	Integration of experimental facilities: A joint effort for establishing a common knowledge base in experimental work on hydrogen safety. <i>International Journal of Hydrogen Energy</i> , 2011 , 36, 2700-2710	6.7	5
37	Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2077-84	2.2	81
36	A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. <i>Leukemia and Lymphoma</i> , 2010 , 51, 252-60	1.9	67
35	A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 609-13	2.7	56
34	Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models. <i>Cancer Biology and Therapy</i> , 2009 , 8, 1893-901	4.6	28
33	Heterogeneity and power in clinical biomarker studies. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1517-21	2.2	22
32	Gene expression profiling of adenosine triphosphate-binding cassette transporters in response to K-ras activation and hypoxia in human pancreatic cancer cell cultures. <i>Pancreas</i> , 2009 , 38, 85-93	2.6	4
31	Antileukemic Effects of the Novel Agent Elesclomol.. <i>Blood</i> , 2009 , 114, 2736-2736	2.2	3
30	Whole blood processing for measurement of signaling proteins by flow cytometry. <i>Current Protocols in Cytometry</i> , 2008 , Chapter 9, Unit 9.27	3.6	8
29	A Phase 2 study of perifosine in advanced or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 87-92	4.4	66
28	Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 1027-36	4	40
27	The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. <i>Human Genetics</i> , 2007 , 121, 635-7	6.3	36
26	Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2184-90	2.2	83
25	Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. <i>Pancreas</i> , 2007 , 35, e16-26	2.6	12
24	Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.. <i>Blood</i> , 2007 , 110, 1505-1505	2.2	

23	Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2006 , 70, 107-14	3.4	45
22	The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. <i>Clinical Cancer Research</i> , 2005 , 11, 8782-8	12.9	378
21	Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2005 , 67, 4-17	4.6	102
20	Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2332-8	2.2	258
19	A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 5526-33	12.9	85
18	Raf kinase as a target for anticancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 677-85	6.1	221
17	Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. <i>Clinical Cancer Research</i> , 2004 , 10, 4464-71	12.9	70
16	Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4410-7	2.2	58
15	The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. <i>Seminars in Radiation Oncology</i> , 2004 , 14, 249-58	5.5	125
14	Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. <i>American Journal of Pathology</i> , 2004 , 164, 557-65	5.8	41
13	NKIAMRE, a novel conserved CDC2-related kinase with features of both mitogen-activated protein kinases and cyclin-dependent kinases. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 308, 784-92	3.4	16
12	Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. <i>Clinical Cancer Research</i> , 2003 , 9, 5666-74	12.9	83
11	Flow cytometric measurement of intracellular pH. <i>Current Protocols in Cytometry</i> , 2001 , Chapter 9, Unit 9.3	3.6	19
10	A comparison in individual murine tumors of techniques for measuring oxygen levels. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 1137-46	4	46
9	A phase II study of temozolomide in advanced untreated pancreatic cancer. <i>Investigational New Drugs</i> , 1998 , 16, 77-9	4.3	20
8	Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998 , 42, 717-21	4	45
7	Flow cytometric determination of glutathione in clinical samples. <i>Cytometry</i> , 1995 , 21, 68-71		17
6	Glutathione and cellular resistance to anti-cancer drugs. <i>Methods in Cell Biology</i> , 1994 , 42 Pt B, 31-44	1.8	15

5	Flow cytometric measurement of lipid peroxidation in vital cells using parinaric acid. <i>Cytometry</i> , 1992 , 13, 686-92		77
4	Relationship between cytoplasmic pH and proliferation during exponential growth and cellular quiescence. <i>Experimental Cell Research</i> , 1987 , 172, 65-75	4.2	92
3	Flow cytometric measurement of cytoplasmic pH: a critical evaluation of available fluorochromes. <i>Cytometry</i> , 1986 , 7, 347-55		117
2	Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis. <i>Journal of Cellular Physiology</i> , 1985 , 124, 61-6	7	18
1	Whole Genomes Define Concordance of Matched Primary, Xenograft, and Organoid Models of Pancreas Cancer		2